What is CRISPR Therapeutics's PP&E (net)?

CRISPR Therapeutics (CRSP) reported PP&E (net) of $112.18M in Q1 2026.

How has CRISPR Therapeutics's PP&E (net) changed year-over-year?

CRISPR Therapeutics's PP&E (net) decreased by 13.3% year-over-year, from $129.43M to $112.18M.

What is the long-term trend for CRISPR Therapeutics's PP&E (net)?

Over 5 years (2020 to 2025), CRISPR Therapeutics's PP&E (net) has grown at a 22.4% compound annual growth rate (CAGR), from $42.16M to $115.85M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

CRISPR Therapeutics CRSP PP&E (Net)

PP&E (Net) at other companies

Beam TherapeuticsBEAM

$101.25M-7.6%

Cogent Biosciences, Inc.COGT

$5.3M-17.9%

CelcuityCELC

$619K+72.9%

Arrowhead ResearchARWR

$374.82M-2.6%

Krystal Biotech, Inc.KRYS

$153.58M+1.7%

BridgeBio PharmaBBIO

$4.94M-26.2%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's PP&E (net)?: CRISPR Therapeutics (CRSP) reported PP&E (net) of $112.18M in Q1 2026.
How has CRISPR Therapeutics's PP&E (net) changed year-over-year?: CRISPR Therapeutics's PP&E (net) decreased by 13.3% year-over-year, from $129.43M to $112.18M.
What is the long-term trend for CRISPR Therapeutics's PP&E (net)?: Over 5 years (2020 to 2025), CRISPR Therapeutics's PP&E (net) has grown at a 22.4% compound annual growth rate (CAGR), from $42.16M to $115.85M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.